Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer
Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed [Yahoo! Finance]
Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed
Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program [Yahoo! Finance]